We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Commercial System Effective for Cefiderocol Susceptibility Testing

By LabMedica International staff writers
Posted on 11 Jul 2019
The novel formulation of the cephalosporin antibiotic makes it very effective against gram-negative non-fastidious bacteria that are otherwise highly resistant to antibiotics, including carbapenem-resistant strains of Enterobacteriaceae and non-fermenters.

In microbiology, the minimum inhibitory concentration (MIC) is the lowest concentration of a chemical, usually a drug, which prevents visible growth of bacterium. More...
MIC depends on the microorganism, the affected human being (in vivo only), and the antibiotic itself.

An international team of scientists working with Thermo Fisher Scientific (Cleveland, Ohio, USA) conducted a study that involved 374 recent clinical isolates, which included Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter spp., Serratia marcescens, Pseudomonas aeruginosa, and Acinetobacter baumannii. One of the four study sites additionally used 147 Centers for Disease Control and Prevention challenge isolates. Three sites also used 11 reproducibility isolates, with three of these isolates being tested each day for three days. Finally, all four sites tested two quality control strains: E. coli ATCC 25922 and P. aeruginosa ATCC 27853.

The team tested a commercially prepared dried minimum inhibitory concentration (MIC) susceptibility system, the Thermo Fisher Scientific Sensititre, and demonstrated an equivalent level of performance compared with the Clinical & Laboratory Standards Institute (CLSI) M07/M100 and the International Organization for Standardization (ISO) 20776-1 reference broth microdilution (BMD) method when testing cefiderocol against Gram-negative non-fastidious organisms.

Overall agreement for the reproducibility (± 1 log2 dilution) concerning the most frequent (or modal) MIC value using automated and manual reading was 95.0% and 95.3%, respectively. The lowest agreement between the two test methods was 90.0% for Enterobacter spp., followed by 92.0% for Citrobacter spp. The strongest agreement was for P. aeruginosa (97.5%). The agreement among the four testing sites was high, at about 95%.

Thomas C. Lewis, BSc, a Research and Development Project Leader at Thermo Fisher Scientific, said, “The high level of agreement obtained by the Sensititre susceptibility system and the CLSI/ISO BMD method suggests that this is an acceptable method for susceptibility testing of cefiderocol. The results are available within 18 to 24 hours, versus several days for the broth. Plus, the testing materials can be kept on the laboratory shelf at room temperature before being used, which is a lot more convenient.” The study was presented at the Annual meeting of the American Society of Microbiology, held June 7-11, 2019, in Atlanta, GA, USA.

Related Links:
Thermo Fisher Scientific


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.